Evofem Biosciences

200 articles about Evofem Biosciences

• Evofem Biosciences and NCODA Announce Collaboration to Educate Oncology Community about Phexxi®, A Non-Hormonal Birth Control Option for Women with Cancer

  2/4/2021

  Evofem Biosciences, Inc., (NASDAQ: EVFM) and NCODA (National Community Oncology Dispensing Association, Inc.), are launching a collaboration to positively impact the quality of life for female patients living with, fighting and recovering from cancer by raising awareness about the importance and availability of a new non-hormonal birth control method, Phexxi®

• Evofem Biosciences Wins Business Intelligence Group's BIG Innovation Award 2021

  1/12/2021

  Evofem honored amongst best companies globally for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi®

• Evofem Biosciences to Participate in Medicaid National Drug Rebate Program for Phexxi® Effective January 1, 2021

  12/22/2020

   Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it has entered into an agreement with the U.S. Centers for Medicare and Medicaid Services (CMS) to participate in the Medicaid National Drug Rebate Program (NDRP), providing access to Phexxi® (lactic acid, citric acid and potassium bitartrate) for the Medicaid population effective January 1, 2021.

• Evofem Biosciences to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference

  12/21/2020

  Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.

• Evofem Biosciences Provides Update on Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea

  12/17/2020

  Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that its pivotal Phase 3 trial, 'EVOGUARD,' of EVO100 for the prevention of chlamydia and gonorrhea remains firmly on schedule

• Evofem Biosciences Announces Orange Book Listing of Two U.S. Patents for Phexxi®

  12/11/2020

  Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that two U.S. patents which cover Phexxi® (lactic acid, citric acid and potassium bitartrate) and its labeled indication are now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

• The U.S. Department of Veterans Affairs Awards Contract to Evofem Biosciences for Phexxi®

  12/3/2020

  Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the U.S. Department of Veterans Affairs (VA) has awarded the Company a contract for the purchase of Phexxi® (lactic acid, citric acid and potassium bitartrate) for a five-year period beginning December 15, 2020.

• Evofem Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference

  11/20/2020

  Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, taking place virtually November 30 through December 3, 2020.

• Evofem Biosciences to Present at Stifel Virtual Healthcare Conference

  11/12/2020

   Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will present at the Stifel Virtual Healthcare Conference on Wednesday November 18, 2020 at 4:00 p.m. ET .

• Evofem Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  11/9/2020

  Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and nine- month periods ended September 30, 2020.

• Evofem Biosciences to Report Third Quarter 2020 Results and Provide Corporate Update on Monday, November 9, 2020

  10/27/2020

  Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the third quarter ended September 30, 2020

• Evofem Biosciences to Participate in Virtual Investor KOL Roundtable

  10/26/2020

  Evofem Biosciences, Inc. (NASDAQ: EVFM) announced today that members of management will participate in a Virtual Investor KOL Roundtable on Thursday, October 29, 2020 at 2:00 p.m. ET.

• Evofem Biosciences Announces First Patient Enrolled in Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea

  10/20/2020

  Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced enrollment of the first patient in its pivotal Phase 3 clinical trial evaluating the safety and efficacy of EVO100 for the prevention of urogenital chlamydia and gonorrhea in women.  

• Evofem Biosciences Secures $25 Million Strategic Investment from Adjuvant Capital

  10/15/2020

  Evofem Biosciences, Inc., (NASDAQ: EVFM) announced today that it has sold $25 million of unsecured convertible promissory notes to funds affiliated with Adjuvant Capital, LP ("Adjuvant Capital"). The notes are convertible into shares of Evofem common stock at a conversion price of $3.65 per share. Proceeds from the sale of the notes

• Evofem Biosciences Announces Updated Date and Time for Fireside Chat at Cantor Global Virtual Healthcare Conference

  9/16/2020

  Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that its virtual fireside chat at the 2020 Cantor Global Virtual Healthcare Conference will take place from 1:20 p.m. to 1:50 p.m. ET on Thursday , September 17, 2020. This is an adjustment from the previously announced date and time. To access the live and archived

• Evofem Biosciences to Present Data at the 2020 STD Prevention Virtual Conference from Phase 2b Trial of EVO100 for Prevention of Chlamydia and Gonorrhea in Women

  9/14/2020

  Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced pivotal results from the Phase 2b AMPREVENCE trial in a poster presentation from the 2020 STD Prevention Virtual Conference, which will take place online September 14 through 24.

• Evofem Biosciences Announces U.S. Commercial Launch of Phexxi™ (lactic acid, citric acid and potassium bitartrate), the First and Only Non-Hormonal, On-Demand Prescription Contraceptive Vaginal Gel

  9/8/2020

  - A First-in-Class Vaginal pH Modulator Designed for Use "In-the-Moment" - - Launch Supported by the Phexxi Concierge Experience, a Robust Telemedicine Support System Designed to Simplify and Speed Access to Phexxi -

• Evofem Biosciences to Participate in Four Upcoming Investor Conferences

  8/31/2020

  Evofem Biosciences, Inc. (NASDAQ: EVFM), a commercial-stage biopharmaceutical company, today announced it will participate in four healthcare equity conferences in September:

• Evofem Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 21, 2020

  8/21/2020

  Evofem Biosciences, Inc., a commercial-stage biopharmaceutical company, announced that on August 18, the Compensation Committee of the Company's Board of Directors approved the grant to 60 new employees of non-qualified stock option awards to purchase an aggregate of 319,200 shares of common stock.

• Evofem Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update

  8/4/2020

  - Advancing Precommercial Activities in Preparation for Phexxi™ Commercial Launch in September 2020 - - Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea on Track for Q4 2020 Initiation - - Management to Host Conference Call Tuesday, August 4, 2020 at 11:00 a.m. EDT -   [04-August-2020]   SAN DIEGO , Aug. 4, 2020 /PRNewswire/ --